Trial reportBlood cancer journal2021
4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.
Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.Frontiers in immunology · 2023Pooled it
- Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.Molecular cancer · 2023Trial
- Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026Review
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- Advances in CAR optimization strategies based on CD28.Frontiers in immunology · 2025Review
- Updates on CAR T cell therapy in multiple myeloma.Biomarker research · 2024Review
- Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.Frontiers in oncology · 2024Review
- Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.Haematologica · 2023Review
- Central nervous system metastasis in a young female patient with primary mediastinal large B-cell lymphoma: A case report and literature review.Surgical neurology international · 2023Article
- The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.Cancers · 2022Review
- Next generations of CAR-T cells - new therapeutic opportunities in hematology?Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.